Lagerstroemia, Euphorbia Hirta, and Kleinhovia Hospita as Inhibitors of Heptad Repeat (HR) SARS‐CoV-2 Spike Protein Based on an In Silico Study

Jantje Wiliem Souhaly, Sapti Puspitarini, M. Hermawan Widyananda, Nashi Widodo


Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-19 (COVID-19), has become a global health issue. Spike proteins from the virus have a vital role in infection. Herbal medicines such as Lagerstroemia, Euphorbia hirta, and Kleinhovia hospita have several pharmacological functions such as anticancer, antiviral, and antioxidant because of their bioactive compound content. Based on an in silico study, this research was conducted on the possibility of phytochemicals from herbal Lagerstroemia, E. hirta, and K. hospita to inhibit spike protein SARS-CoV-2. A three-dimensional (3D) compound structure of each herbal medicine was docked with HR protein using AutoDock Vina software. The docking result, which has the best binding energy value, is continued with the analysis of molecular dynamics simulation. Lagerine, rutin, and nicotiflorin compounds might bind to proteins with lower binding energy. Protein was unstable when complexed with compounds compared with control, as seen from the root-mean-square deviation (RMSD) value. Therefore, this research is pre-experimental to inhibit SARS-CoV-2 spike proteins by herbal medicines.


Keywords: COVID-19, Euphorbia hirta, Kleinhovia hospita, Lagerstroemia, severe acute respiratory syndrome-coronavirus 2.


Full Text:



NUGRAHA R. V., RIDWANSYAH H., GHOZALI M., KHAIRANI A. F., and ATIK N. Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. Evidence-Based Complementary and Alternative Medicine, 2020, 2020: e2560645.

PANYOD S., HO C.T., and SHEEN L.Y. Dietary Therapy and Herbal Medicine for COVID-19 Prevention: A Review and Perspective. Journal of Traditional and Complementary Medicine, 2020, 10(4): 420–427.

DI MATTEO G., SPANO M., GROSSO M., SALVO A., INGALLINA C., RUSSO M., RITIENI A., and MANNINA L. Food and COVID-19: Preventive/Co-Therapeutic Strategies Explored by Current Clinical Trials and in Silico Studies. Foods, 2020, 9(8): E1036.

JHA A. K., KUMAR R., GOENKA M. K., and DAYAL V. M. Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update. Journal of Digestive Endoscopy, 2020, 11(1): 69-72.

MCKEE D. L., STERNBERG A., STANGE U., LAUFER S., and NAUJOKAT C. Candidate Drugs against SARS-CoV-2 and COVID-19. Pharmacological Research, 2020, 157: 104859.

DAI W., ZHANG B., JIANG X. M., SU H., LI J., ZHAO Y., XIE X., JIN Z., PENG J., LIU F., LI C., LI Y., BAI F., WANG H., CHENG X., CEN X., HU S., YANG X., WANG J., LIU X., XIAO G., JIANG H., RAO Z., ZHANG L. K., XU Y., YANG H., and LIU H. Structure-Based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science, 2020, 368(6497): 1331–1335.

XIA S., LIU M., WANG C., XU W., LAN Q., FENG S., QI F., BAO L., DU L., LIU S., QIN C., SUN F., SHI Z., ZHU Y., JIANG S., and LU L. Inhibition of SARS-CoV-2 (Previously 2019-NCoV) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting Its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion. Cell Research, 2020, 30(4): 343–355.

ZHANG L., LIN D., SUN X., CURTH U., DROSTEN C., SAUERHERING L., BECKER S., ROX K., and HILGENFELD R. Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved α-Ketoamide Inhibitors. Science, 2020, 368(6489): 409–412.

XIA S., LIU M., WANG C., XU W., LAN Q., FENG S., QI F., BAO L., DU L., LIU S., QIN C., SUN F., SHI Z., ZHU Y., JIANG S., and LU L. Inhibition of SARS-CoV-2 (Previously 2019-NCoV) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting Its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion. Cell Research, 2020, 30(4): 343–355.

WALLS A. C., PARK Y. J., TORTORICI M. A., WALL A., MCGUIRE A. T., and VEESLER D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, 2020, 181(2): 281-292.e6.

HARVEY A. L., EDRADA-EBEL R., and QUINN R. J. The Re-Emergence of Natural Products for Drug Discovery in the Genomics Era. Nature Reviews Drug Discovery, 2015, 14(2): 111–129.

YANG Y., ISLAM M. S., WANG J., LI Y., and CHEN X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. International Journal of Biological Sciences, 2020, 16(10): 1708–1717.

SHAHRAJABIAN M. H., SUN W., SHEN H., and CHENG Q. Chinese Herbal Medicine for SARS and SARS-CoV-2 Treatment and Prevention, Encouraging Using Herbal Medicine for COVID-19 Outbreak. Acta Agriculturae Scandinavica, Section B — Soil & Plant Science, 2020, 70(5): 437–443.

RUSMANA D., WAHYUDIANINGSIH R., ELISABETH M., BALQIS B., MAESAROH M., and WIDOWATI W. Antioxidant Activity of Phyllanthus Niruri Extract, Rutin and Quercetin. The Indonesian Biomedical Journal, 2017, 9(2): 84-90.

FRANCENIA SANTOS-SÁNCHEZ N., SALAS-CORONADO R., VILLANUEVA-CAÑONGO C., and HERNÁNDEZ-CARLOS B. Antioxidant Compounds and Their Antioxidant Mechanism. In: SHALABY E. (ed.) Antioxidants. IntechOpen, London, 2019.

KHAN M. R., HUANG C., ZHAO H., HUANG H., REN L., FAIQ M., HASHMI M. S., LI B., ZHENG D., XU Y., SU H., and AN J. Antioxidant activity of thymol essential oil and inhibition of polyphenol oxidase enzyme: A case study on the enzymatic browning of harvested longan fruit. Chemical and Biological Technologies in Agriculture, 2021, 8(1): 61.

DALLAKYAN S., and OLSON A. J. Small-Molecule Library Screening by Docking with PyRx. In: HEMPEL J., WILLIAMS C., and HONG C. (eds.) Chemical Biology. Methods in Molecular Biology, Vol. 1263. Humana Press, New York, 2015: 243–250.

JAGHOORI M. M., LEIJLEVENS B., and OLABARRIAGA S. D. 1001 Ways to run AutoDock Vina for virtual screening. Journal of Computer-Aided Molecular Design, 2016, 30(3): 237–249.

VISHNUVARTHAN V. J. In-Silico Screening of Flavonoids targeted for Death Receptors in Cancer by Using Hex Molecular Docking. Journal of Young Pharmacists, 2017, 9(2): 168–171.

KRIEGER E., and VRIEND G. New Ways to Boost Molecular Dynamics Simulations. Journal of Computational Chemistry, 2015, 36(13): 996–1007.

GHOSH R., CHAKRABORTY A., BISWAS A., and CHOWDHURI S. Identification of Polyphenols from Broussonetia Papyrifera as SARS CoV-2 Main Protease Inhibitors Using in Silico Docking and Molecular Dynamics Simulation Approaches. Journal of Biomolecular Structure and Dynamics, 2021, 39(17): 6747–6760.

MARTÍNEZ L. Automatic Identification of Mobile and Rigid Substructures in Molecular Dynamics Simulations and Fractional Structural Fluctuation Analysis. PLoS ONE, 2015, 10(3): e0119264.

XIA S., ZHU Y., LIU M., LAN Q., XU W., WU Y., YING T., LIU S., SHI Z., JIANG S., and LU L. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cellular & Molecular Immunology, 2020, 17(7): 765–767.

OU X., LIU Y., LEI X., LI P., MI D., REN L., GUO L., GUO R., CHEN T., HU J., XIANG Z., MU Z., CHEN X., CHEN J., HU K., JIN Q., WANG J., and QIAN Z. Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity with SARS-CoV. Nature Communications, 2020, 11(1): 1620.

RAGAB D., SALAH ELDIN H., TAEIMAH M., KHATTAB R., and SALEM R. The COVID-19 Cytokine Storm; What We Know So Far. Frontiers in Immunology, 2020, 11: 1446.

SOY M., KESER G., ATAGÜNDÜZ P., TABAK F., ATAGÜNDÜZ I., and KAYHAN S. Cytokine Storm in COVID-19: Pathogenesis and Overview of Anti-Inflammatory Agents Used in Treatment. Clinical Rheumatology, 2020, 39(7): 2085–2094.

VASEEHARAN B., and THAYA R. Medicinal Plant Derivatives as Immunostimulants: An Alternative to Chemotherapeutics and Antibiotics in Aquaculture. Aquaculture International, 2014, 22: 1079–1091.

WORLD HEALTH ORGANIZATION. WHO Coronavirus (COVID-19) Dashboard, n.d.




  • There are currently no refbacks.